Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study
- 11 April 2008
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 371 (9619), 1181-1189
- https://doi.org/10.1016/s0140-6736(08)60524-3
Abstract
No abstract availableThis publication has 20 references indexed in Scilit:
- Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled studyThe Lancet, 2007
- Vacinas contra rotavírus e papilomavírus humano (HPV)Jornal de Pediatria, 2006
- Rotavirus vaccines: current prospects and future challengesThe Lancet, 2006
- Rotavirus and Severe Childhood DiarrheaEmerging Infectious Diseases, 2006
- Safety and Efficacy of an Attenuated Vaccine against Severe Rotavirus GastroenteritisThe New England Journal of Medicine, 2006
- Clinical and Epidemiological Aspects of Rotavirus InfectionPediatric Annals, 2006
- Rotarix: Development of a Live Attenuated Monovalent Human Rotavirus VaccinePediatric Annals, 2006
- Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccineReviews in Medical Virology, 2004
- Rotavirus vaccines and vaccination in Latin America.Revista Panamericana de Salud Pública, 2000
- Rotavirus Infection in Infants as Protection against Subsequent InfectionsThe New England Journal of Medicine, 1996